Indication

Psoriasis

Clinical and regulatory intelligence for Psoriasis with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Assets: 3

Relevant assets

Janssen →

NHLBI →

Phase →

Relevant companies

Hangzhou Zhongmei Huadong Pharmaceutical →

Recent signals(3)

ClinicalJuly 4, 2026

Study on Psoriasis and Cardiometabolic Disease Relationship Launched by NHLBI

The NHLBI has initiated a study to explore the relationship between psoriasis and cardiometabolic diseases.

ClinicalJune 26, 2026

Janssen's Guselkumab Trial Targets Skin of Color Patients with Psoriasis

A clinical trial is underway to assess the efficacy of guselkumab in skin of color participants with moderate-to-severe psoriasis.

ClinicalJune 24, 2026

Phase III Trial of MC2-01 Cream for Plaque Psoriasis Shows Efficacy and Safety

A Phase III trial is underway to evaluate the efficacy and safety of MC2-01 cream compared to existing treatments in plaque psoriasis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Dermatology →

Psoriasis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.